Search

Displaying results 6631 - 6640 of 10000 in total
  1. Drug

    Saccharomyces cerevisiae

    go.drugbank.com/drugs/DB10447
    Approved

    Saccharomyces cerevisiae is used in allergenic testing.

  2. Drug

    Oxyphenbutazone

    go.drugbank.com/drugs/DB03585
    ApprovedWithdrawn

    Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.

  3. Drug

    PF-05212377

    go.drugbank.com/drugs/DB16044
    Investigational

    on Donepezil). … PF-05212377 is under investigation in clinical trial NCT01712074 (Study Evaluating Thesafety and Efficacy of PF-05212377 or Placebo in Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms

  4. Drug

    Elinogrel

    go.drugbank.com/drugs/DB06350
    Investigational

    A P2Y12 inhibitor and platelet aggregation inhibitor.

  5. Drug

    Acetylcysteine zinc

    go.drugbank.com/drugs/DB14479
    Investigational

    Synonyms: N-acetyl-L-cysteine zinc saltCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Calmangafodipir

    go.drugbank.com/drugs/DB18398
    Investigational

    Synonyms: Calcium,n,n'-1,2-ethanediylbis(n-((3-hydroxy-2-methyl-5-((phosphonooxy)methyl)-4-pyridinyl)methyl)glycine) manganese complexes trisodium trihydrogen manganateCategories: Compounds used in a research, industrial, or household setting
  7. Drug

    Lawsone

    go.drugbank.com/drugs/DB04744
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Quinacrine mustard

    go.drugbank.com/drugs/DB02240
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Branaplam

    go.drugbank.com/drugs/DB14918
    Investigational

    Branaplam is under investigation in clinical trial NCT02268552 (An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)).

  10. Drug

    Firtecan pegol

    go.drugbank.com/drugs/DB14953
    Investigational

    Firtecan pegol is under investigation in clinical trial NCT01036113 (A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer).